JP Morgan Downgrades Andrx

Analyst Corey Davis cites the pharmaceutical company's dismal quarterly report

JP Morgan downgraded pharmaceutical-company Andrx (ADRX ) to underweight from overweight.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.